S&P 500   4,320.06
DOW   33,963.84
QQQ   357.91
52-week Low Names To Tip The Upside Scale In Your Favor
BREAKING: Tiny biotech successfully treats blindness (Ad)
3 Reasons This Sleeping Giant Is About To Wake Up
Things to know about California's new proposed rules for insurance companies
Laser breakthrough could send stock soaring 2,467% (Ad)
KB Home Price Weakness is a Signal to Buy this Cash Machine
Analysts Went All In On These Computer Stocks, Save Your Spot
Laser breakthrough could send stock soaring 2,467% (Ad)
Seagen, Activision Blizzard rise; Scholastic, Intel fall, Friday, 9/22/2023
How major US stock indexes fared Friday, 9/22/2023
S&P 500   4,320.06
DOW   33,963.84
QQQ   357.91
52-week Low Names To Tip The Upside Scale In Your Favor
BREAKING: Tiny biotech successfully treats blindness (Ad)
3 Reasons This Sleeping Giant Is About To Wake Up
Things to know about California's new proposed rules for insurance companies
Laser breakthrough could send stock soaring 2,467% (Ad)
KB Home Price Weakness is a Signal to Buy this Cash Machine
Analysts Went All In On These Computer Stocks, Save Your Spot
Laser breakthrough could send stock soaring 2,467% (Ad)
Seagen, Activision Blizzard rise; Scholastic, Intel fall, Friday, 9/22/2023
How major US stock indexes fared Friday, 9/22/2023
S&P 500   4,320.06
DOW   33,963.84
QQQ   357.91
52-week Low Names To Tip The Upside Scale In Your Favor
BREAKING: Tiny biotech successfully treats blindness (Ad)
3 Reasons This Sleeping Giant Is About To Wake Up
Things to know about California's new proposed rules for insurance companies
Laser breakthrough could send stock soaring 2,467% (Ad)
KB Home Price Weakness is a Signal to Buy this Cash Machine
Analysts Went All In On These Computer Stocks, Save Your Spot
Laser breakthrough could send stock soaring 2,467% (Ad)
Seagen, Activision Blizzard rise; Scholastic, Intel fall, Friday, 9/22/2023
How major US stock indexes fared Friday, 9/22/2023
S&P 500   4,320.06
DOW   33,963.84
QQQ   357.91
52-week Low Names To Tip The Upside Scale In Your Favor
BREAKING: Tiny biotech successfully treats blindness (Ad)
3 Reasons This Sleeping Giant Is About To Wake Up
Things to know about California's new proposed rules for insurance companies
Laser breakthrough could send stock soaring 2,467% (Ad)
KB Home Price Weakness is a Signal to Buy this Cash Machine
Analysts Went All In On These Computer Stocks, Save Your Spot
Laser breakthrough could send stock soaring 2,467% (Ad)
Seagen, Activision Blizzard rise; Scholastic, Intel fall, Friday, 9/22/2023
How major US stock indexes fared Friday, 9/22/2023
NASDAQ:VXRT

Vaxart (VXRT) Competitors

$0.71
0.00 (0.00%)
(As of 09/22/2023 ET)
Compare
Today's Range
$0.69
$0.72
50-Day Range
$0.69
$0.85
52-Week Range
$0.56
$2.35
Volume
629,517 shs
Average Volume
716,010 shs
Market Capitalization
$108.39 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$2.75

VXRT vs. CCCC, OPT, KOD, GMDA, OCGN, JATT, GNTA, TSBX, BCAB, and CDTX

Should you be buying Vaxart stock or one of its competitors? The main competitors of Vaxart include C4 Therapeutics (CCCC), Opthea (OPT), Kodiak Sciences (KOD), Gamida Cell (GMDA), Ocugen (OCGN), JATT Acquisition (JATT), Genenta Science (GNTA), Turnstone Biologics (TSBX), BioAtla (BCAB), and Cidara Therapeutics (CDTX). These companies are all part of the "biological products, except diagnostic" industry.

Vaxart vs.

C4 Therapeutics (NASDAQ:CCCC) and Vaxart (NASDAQ:VXRT) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their valuation, media sentiment, analyst recommendations, community ranking, earnings, risk, institutional ownership, profitability and dividends.

C4 Therapeutics presently has a consensus price target of $10.13, indicating a potential upside of 396.32%. Vaxart has a consensus price target of $2.75, indicating a potential upside of 285.59%. Given Vaxart's higher probable upside, research analysts plainly believe C4 Therapeutics is more favorable than Vaxart.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
C4 Therapeutics
2 Sell rating(s)
3 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.00
Vaxart
0 Sell rating(s)
1 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.67

Vaxart has lower revenue, but higher earnings than C4 Therapeutics. Vaxart is trading at a lower price-to-earnings ratio than C4 Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
C4 Therapeutics$31.10M3.23-$128.18M-$2.85-0.72
Vaxart$110K985.32-$107.76M-$0.76-0.94

In the previous week, C4 Therapeutics and C4 Therapeutics both had 1 articles in the media. Vaxart's average media sentiment score of 0.00 equaled C4 Therapeutics'average media sentiment score.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
C4 Therapeutics
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Vaxart
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

C4 Therapeutics has a beta of 2.07, indicating that its stock price is 107% more volatile than the S&P 500. Comparatively, Vaxart has a beta of 0.64, indicating that its stock price is 36% less volatile than the S&P 500.

Vaxart received 288 more outperform votes than C4 Therapeutics when rated by MarketBeat users. Likewise, 65.39% of users gave Vaxart an outperform vote while only 35.71% of users gave C4 Therapeutics an outperform vote.

CompanyUnderperformOutperform
C4 TherapeuticsOutperform Votes
20
35.71%
Underperform Votes
36
64.29%
VaxartOutperform Votes
308
65.39%
Underperform Votes
163
34.61%

Vaxart has a net margin of 0.00% compared to Vaxart's net margin of -872.34%. Vaxart's return on equity of -50.69% beat C4 Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
C4 Therapeutics-872.34% -50.69% -33.63%
Vaxart N/A -99.00%-69.40%

74.9% of C4 Therapeutics shares are owned by institutional investors. Comparatively, 19.0% of Vaxart shares are owned by institutional investors. 8.0% of C4 Therapeutics shares are owned by company insiders. Comparatively, 3.0% of Vaxart shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Summary

C4 Therapeutics beats Vaxart on 8 of the 15 factors compared between the two stocks.


Get Vaxart News Delivered to You Automatically

Sign up to receive the latest news and ratings for VXRT and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding VXRT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

VXRT vs. The Competition

MetricVaxartBiological Products IndustryMedical SectorNASDAQ Exchange
Market Cap$108.07M$2.54B$4.45B$6.28B
Dividend YieldN/A2.23%2.49%6.49%
P/E Ratio-0.947.10131.0512.89
Price / Sales985.32133.172,859.3955.62
Price / CashN/A25.5592.66102.84
Price / Book0.853.484.074.84
Net Income-$107.76M$63.38M$123.02M$186.12M
7 Day Performance0.63%0.10%-1.70%-2.19%
1 Month Performance-15.22%-6.60%-2.79%-4.93%
1 Year Performance-66.04%20.56%10.00%5.76%

Vaxart Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
CCCC
C4 Therapeutics
1.608 of 5 stars
$2.21
+2.8%
$10.13
+358.1%
-76.3%$108.71M$31.10M-0.78146News Coverage
OPT
Opthea
1.4899 of 5 stars
$1.88
-1.1%
$16.25
+764.4%
-71.6%$109.79M$110,000.000.002,021Gap Up
KOD
Kodiak Sciences
2.6735 of 5 stars
$2.10
-1.9%
$7.33
+249.2%
-77.1%$110.15MN/A-0.37118Positive News
GMDA
Gamida Cell
1.7315 of 5 stars
$1.03
-3.7%
$7.60
+637.9%
-56.5%$112.98MN/A-1.78143Gap Down
OCGN
Ocugen
1.7478 of 5 stars
$0.40
flat
$3.50
+770.9%
-78.3%$103.08M$42.62M-1.0984Positive News
JATT
JATT Acquisition
0 of 5 stars
$5.75
-7.0%
N/A-38.8%$99.19MN/A0.002,021High Trading Volume
GNTA
Genenta Science
2.1459 of 5 stars
$5.42
-1.3%
$20.00
+269.0%
+16.2%$98.75MN/A0.004Positive News
TSBX
Turnstone Biologics
1.8579 of 5 stars
$4.31
+0.2%
$19.00
+340.8%
N/A$98.44M$73.30M0.00108Gap Up
BCAB
BioAtla
1.8488 of 5 stars
$2.01
+3.1%
$15.33
+662.9%
-78.9%$96.08M$250,000.00-0.7666
CDTX
Cidara Therapeutics
2.4202 of 5 stars
$1.05
-1.9%
$4.67
+344.4%
+39.8%$94.76M$64.29M-8.0873Analyst Report
News Coverage

Related Companies and Tools

This page (NASDAQ:VXRT) was last updated on 9/23/2023 by MarketBeat.com Staff

My Account -